Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | PYGL | P06737 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31736572 | 1.00 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1PYGLMAPTHPGD | |
| SCHEMBL28503213 | 0.85 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1PYGLKMT2ARAB9A | |
| SCHEMBL28637889 | 0.84 | KAT6A (0.54) | ALDH1A1L3MBTL1MAPTHPGDKDM4E | |
| SCHEMBL1818135 | 0.78 | ALDH1A1 (0.80) | ALDH1A1L3MBTL1MAPTHPGDKMT2A | |
| SCHEMBL10298010 | 0.77 | TSHR (0.53) | ALDH1A1L3MBTL1KDM4ERAB9ANPC1 | |
| SCHEMBL28500714 | 0.76 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1PYGLMAPTHPGD | |
| SCHEMBL29215335 | 0.75 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1PYGLMAPTHPGD | |
| SCHEMBL60081 | 0.74 | TSHR (0.52) | ALDH1A1L3MBTL1MAPTKMT2ARAB9A | |
| SCHEMBL31736470 | 0.73 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1PYGLMAPTKMT2A | |
| SCHEMBL4238456 | 0.73 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1PYGLMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. | 2010-05-13 | — | — | US | claimed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11497736-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3889142-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3632902-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3549936-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210038572-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006110483-A1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PCT THERAPEUTICS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497736-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | SMN1; SMN2, UPF1, VHL | ALDH1A1 1412/4885L3MBTL1 122/4885PYGL 520/4885 |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | ALDH1A1 1628/4885L3MBTL1 236/4885PYGL 757/4885 |
| US-20210038572-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | ALDH1A1 1185/4885L3MBTL1 16/4885PYGL 1717/4885 |
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | SMN1; SMN2, UPF1, VHL | ALDH1A1 1412/4885L3MBTL1 122/4885PYGL 520/4885 |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | ALDH1A1 2018/4885L3MBTL1 51/4885PYGL 1615/4885 |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | ALDH1A1 1785/4885L3MBTL1 42/4885PYGL 1401/4885 |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | ALDH1A1 2175/4885L3MBTL1 49/4885PYGL 989/4885 |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | UPF1, PABPC1, PABPC4 | ALDH1A1 1665/4885L3MBTL1 107/4885PYGL 1008/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | ALDH1A1 2766/4885L3MBTL1 78/4885PYGL 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.